Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials

Amaia Eleonora Maennling, Mehmet Kemal Tur, Marcus Niebert, Torsten Klockenbring, Felix Zeppernick, Stefan Gattenloehner, Ivo Meinhold-Heerlein, Ahmad Fawzi Hussain*

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

Original languageEnglish
Article number1826
Number of pages19
JournalCancers
Volume11
Issue number12
DOIs
Publication statusPublished - Dec 2019

Keywords

  • epidermal growth factor receptor
  • antibody
  • antibody drug conjugate
  • tyrosine kinase inhibitor
  • chimeric antigen receptors t cells
  • GROWTH-FACTOR RECEPTOR
  • RANDOMIZED PHASE-II
  • MONOCLONAL-ANTIBODY
  • CHEMOTHERAPY PLUS
  • TYROSINE KINASES
  • ERBB RECEPTORS
  • TRASTUZUMAB
  • COMBINATION
  • HER2
  • EXPRESSION

Cite this

Maennling, A. E., Tur, M. K., Niebert, M., Klockenbring, T., Zeppernick, F., Gattenloehner, S., Meinhold-Heerlein, I., & Hussain, A. F. (2019). Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. Cancers, 11(12), [1826]. https://doi.org/10.3390/cancers11121826